Abstract
The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem β-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.
Original language | English (US) |
---|---|
Pages (from-to) | 972-980 |
Number of pages | 9 |
Journal | Clinical Infectious Diseases |
Volume | 64 |
Issue number | 7 |
DOIs | |
State | Published - Apr 1 2017 |
Keywords
- Carbapenems
- Cefepime
- Cephamycins
- ESBLs
- Piperacillin-tazobactam
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases